Metformin and survival in diabetic patients with breast cancer

Journal of the Egyptian Public Health Association

Volumn 89, Issue 3, 2014, Pages 148-153

  El Benhawy, Sanaa A ^a   El Sheredy, Heba G ^b  

^a Radiation Sciences Department   (Canada)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Breast cancer; diabetes mellitus; metformin; survival outcomes

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE FREE SURVIVAL; EGYPT; EPIDEMIOLOGY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; TEACHING HOSPITAL;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; EGYPT; FEMALE; HOSPITALS, TEACHING; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84920085817     PISSN: 00132446     EISSN: 2090262X     Source Type: Journal    
DOI: 10.1097/01.EPX.0000456620.00173.c0     Document Type: Article

References (27)

1. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121:856-862.
2. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159:1160-1167.
3. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2:48-53.
4. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008; 109:389-395.
5. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569-578.
6. Carmichael AR. Obesity and prognosis of breast cancer. Obes Rev 2006; 7:333-340.
7. Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions. JClinOncol 2008; 26:833-834.
8. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
9. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620-1625.
10. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52:1766-1777.
11. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33:1304-1308.
12. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-10812.
13. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 2010; 123:591-596.
14. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8:909-915.
15. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8:2031-2040.
16. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69:7507-7511.
17. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, et al. AJCC Cancer Staging Manual, sixth edition. Ann Oncol 2003; 14:345-346.
18. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 2009; 18:701-705.
19. Lega I, Austin P, Gruneir A, Goodwin P, Rochon P, Lipscombe L. Association between metformin therapy and mortality after breast cancer: a populationbased study. Diabetes Care 2013; 36:3018-3026.
20. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2 + breast cancer. Ann Oncol 2012; 23:1771-1780.
21. Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of 1013 breast cancer patients with diabetes. Breast Cancer Res Treat 2013; 137:807-816.
22. Jiralerspong S, Palla SL, Giordano SH, Bernstam MF, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297-3302.
23. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29:254-258.
24. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009; 27:3271-3273.
25. Bayrakter S, Hernadez AL, Lei X, Meric BF, Liton JK, Hortobagyi GN, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012; 118:1202-1211.
26. Lund SS, Tarnow L, Stehouwer C, Schalkwijk G, Winther K, Frandsen M, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in nonobese patients with type 2 diabetes. Eur J Endocrinol 2008; 158:631-641.
27. Ersoy C, Kiyici S, Budak F, Oral B, Guclu M, Duran C, et al. The effect of metformin treatment on VEGF and PAI 1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 2008; 81:56-60.